News | May 27, 2022
Torrent Pharma acquires four brands from Dr Reddy’s
The integration and transition of the brands are expected to be completed by June 2022.
The integration and transition of the brands are expected to be completed by June 2022.
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Ind-Ra expects revenue growth of over 12% in 2022.
Flattish volume growth and subdued new launches were key factors for last month
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The segment delivered strong sales growth of 20% YoY
Domestic business was up 41.9% YoY and 27.7% QoQ
Subscribe To Our Newsletter & Stay Updated
